Kiniksa Pharmaceuticals Ltd - Asset Resilience Ratio

Latest as of March 2026: 33.70%

Kiniksa Pharmaceuticals Ltd (KNSA) has an Asset Resilience Ratio of 33.70% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Kiniksa Pharmaceuticals Ltd for a breakdown of total debt and financial obligations.

Liquid Assets

$278.14 Million

Cash + Short-term Investments

Total Assets

$825.28 Million

All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Kiniksa Pharmaceuticals Ltd's Asset Resilience Ratio has changed over time. See KNSA total equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Kiniksa Pharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Kiniksa Pharmaceuticals Ltd (KNSA) total market value.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$278.14 Million	33.7%
Total Liquid Assets	$278.14 Million	33.70%

Asset Resilience Insights

Very High Liquidity: Kiniksa Pharmaceuticals Ltd maintains exceptional liquid asset reserves at 33.70% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Kiniksa Pharmaceuticals Ltd Industry Peers by Asset Resilience Ratio

Compare Kiniksa Pharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Takeda Pharmaceutical Company Limited F:TKDA	Drug Manufacturers - Specialty & Generic	0.69%
Swedish Orphan Biovitrum AB (publ) ST:SOBI	Drug Manufacturers - Specialty & Generic	1.54%
Yunnan Baiyao Group Co Ltd SHE:000538	Drug Manufacturers - Specialty & Generic	8.38%
Cipla Limited NSE:CIPLA	Drug Manufacturers - Specialty & Generic	20.75%
Alkem Laboratories Limited NSE:ALKEM	Drug Manufacturers - Specialty & Generic	31.91%
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt F:RIG2	Drug Manufacturers - Specialty & Generic	0.20%
Yuhan Corp. KO:000100	Drug Manufacturers - Specialty & Generic	0.92%
Guobang Pharma Ltd SHG:605507	Drug Manufacturers - Specialty & Generic	11.00%

Annual Asset Resilience Ratio for Kiniksa Pharmaceuticals Ltd (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Kiniksa Pharmaceuticals Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	32.54%	$248.48 Million	$763.63 Million	+22.20pp
2024-12-31	10.34%	$60.05 Million	$580.55 Million	-8.36pp
2023-12-31	18.70%	$98.42 Million	$526.32 Million	+3.93pp
2022-12-31	14.77%	$67.89 Million	$459.67 Million	-10.89pp
2021-12-31	25.66%	$59.73 Million	$232.80 Million	-34.28pp
2020-12-31	59.93%	$209.44 Million	$349.46 Million	-13.32pp
2019-12-31	73.25%	$186.45 Million	$254.53 Million	+0.16pp
2018-12-31	73.09%	$235.33 Million	$321.96 Million	+72.87pp
2017-12-31	0.22%	$105.00K	$47.49 Million	+0.04pp
2016-12-31	0.19%	$105.00K	$56.47 Million	--

pp = percentage points

About Kiniksa Pharmaceuticals Ltd

NASDAQ:KNSA USA Drug Manufacturers - Specialty & Generic

Market Cap

$2.45 Billion

Market Cap Rank

#5687 Global

#1779 in USA

Share Price

$52.86

Change (1 day)

-0.71%

52-Week Range

$26.33 - $59.48

All Time High

$59.48